Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
The postpartum depression market growth is expected to accelerate over the coming years, driven by increasing awareness, improved screening practices, and rising diagnosis rates among new mothers. The market is also benefiting from the introduction of novel therapies, including Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others, and innovative drug delivery approaches that address unmet clinical needs.
LAS VEGAS, Aug. 25, 2026 /PRNewswire/ -- Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Postpartum Depression Market Summary
Discover more about the global postpartum depression drugs industry @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Key Factors Driving the Growth of the Postpartum Depression Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, luvesilocin represents one of the most differentiated pipeline assets due to its novel serotonergic neuroplastogen mechanism and potential to deliver rapid and durable antidepressant effects following a single administration. Meanwhile, LPCN 1154 and NORA520 are expanding the neuroactive steroid class, with both candidates aiming to optimize GABA-A receptor modulation and provide rapid symptom improvement.
Postpartum Depression Market Analysis
Postpartum Depression Competitive Landscape
Some of the postpartum depression drugs under development include Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others.
Reunion Neuroscience's Luvesilocin is a proprietary, patented prodrug of 4-OH-DiPT being developed as a potential best-in-class therapy and is administered through a subcutaneous (SC) injection. The company plans to begin a pivotal Phase III clinical trial for postpartum depression (PPD) in 2026, with positive outcomes potentially supporting its regulatory approval. Luvesilocin has received Breakthrough Therapy Designation (BTD) from the US FDA for the treatment of PPD. In the Phase II RECONNECT trial involving adult women with moderate-to-severe PPD, the candidate produced substantial improvements in depressive symptoms while demonstrating a generally favorable safety and tolerability profile.
Lipocine's LPCN 1154 is an oral formulation of brexanolone, a non-SSRI therapy that is chemically identical to the naturally occurring neurosteroid allopregnanolone. The candidate is being developed as a potential rescue treatment for PPD, offering rapid symptom relief within hours without requiring intensive patient monitoring. LPCN 1154 has shown clinically meaningful tolerability with minimal central nervous system (CNS) depressant effects and avoids the dissociative or hallucinogenic risks associated with psychedelic-based therapies, making it a promising option for safe at-home treatment while supporting the maternal–infant bond. Lipocine has submitted applications to the FDA for Breakthrough Therapy and Fast Track designations and has also filed the Phase III validation study protocol as part of its planned regulatory pathway.
The anticipated launch of these emerging therapies are poised to transform the postpartum depression market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the postpartum depression market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the postpartum depression drugs in development @ Postpartum Depression Clinical Development
Recent Developments in the Postpartum Depression Market
Postpartum Depression Epidemiology Segmentation
The postpartum depression epidemiology section provides insights into the historical and current postpartum depression patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for the largest share of diagnosed prevalent cases of maternal PPD in 2025, with ~700,000 cases. The postpartum depression treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Postpartum Depression Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Postpartum Depression Epidemiology Segmentation
Maternal PPD Total Diagnosed Prevalent Cases
Key Postpartum Depression Companies
Reunion Neuroscience, TWi Biotechnology, Lipocine, GH Research, Sage Therapeutics, Biogen, and others
Key Postpartum Depression Therapies
Luvesilocin (RE104), NORA520, LPCN 1154, GH001, ZURZUVAE, and others
Scope of the Postpartum Depression Market Report
Download the report to understand the postpartum depression drug market @ Postpartum Depression Treatment Market
Table of Contents
1
Postpartum Depression Market Key Insights
2
Postpartum Depression Market Report Introduction
3
Executive Summary of Postpartum Depression (PPD)
4
Key Events
5
Epidemiology and Market Methodology of Postpartum Depression (PPD)
6
Postpartum Depression (PPD) Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2
Market Share of Postpartum Depression (PPD) By Therapies (%) in the 7MM in 2025
6.3
Market Share of Postpartum Depression (PPD) By Therapies (%) in the 7MM in 2036
7
Disease Background And Overview of Postpartum Depression (PPD)
7.1
Introduction
7.2
Causes
7.3
Signs And Symptoms
7.4
Diagnosis
7.5
Treatment and Management
8
Epidemiology and Patient Population of Postpartum Depression (PPD)
8.1
Key Findings
8.2
Assumption and Rationale
8.3
Maternal PPD Total Diagnosed Prevalent Cases in the 7MM
8.4
The United States
8.4.1
Maternal PPD Total Diagnosed Prevalent Cases in the United States
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey of Postpartum Depression (PPD)
10
Marketed Postpartum Depression Therapies
10.1
Marketed Competitive Landscape of Postpartum Depression (PPD)
10.2
Zuranolone (ZURZUVAE): Sage Therapeutics and Biogen
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Analyst Views
To be continued in the report…
11
Emerging Postpartum Depression Therapies
11.1
Emerging Competitive Landscape of Postpartum Depression (PPD)
11.2
Luvesilocin (RE104): Reunion Neuroscience
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
LPCN 1154: Lipocine
To be continued in the report…
12
Postpartum Depression Market: Seven Major Market Analysis
12.1
Key Findings
12.2
Market Outlook of Postpartum Depression (PPD)
12.3
Conjoint Analysis of Postpartum Depression (PPD)
12.4
Key Market Forecast Assumptions
12.5
Total Market Size of Postpartum Depression (PPD) in the 7MM
12.6
The United States Postpartum Depression Market
12.6.1
Total Market Size of Postpartum Depression (PPD) in the United States
12.6.2
Market Size of Postpartum Depression (PPD) by Therapies in the United States
12.7
EU4 and the UK Postpartum Depression Market
12.8
Japan Postpartum Depression Market
13
Unmet Needs of Postpartum Depression (PPD)
14
SWOT Analysis of Postpartum Depression (PPD)
15
KOL Views of Postpartum Depression (PPD)
16
Postpartum Depression Market Access and Reimbursement
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
16.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5
Market Access and Reimbursement of Postpartum Depression (PPD) Therapies
17
Bibliography
18
Postpartum Depression Market Report Methodology
Related Reports
Postpartum Depression Clinical Trial Analysis
Postpartum Depression Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PPD companies, including GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
Maternal Mental Health Market
Maternal Mental Health Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key maternal mental health companies, including Biogen Inc., Sage Therapeutics, Inc., Therapy Mama., Canopie., Postpartum Support International, SonderMind Inc., Maven Clinic Co., Wildflower Health, Hims & Hers Health, Inc., Medela, Bausch Health Companies Inc., Maternal Mental Health Alliance, MumsAid, Cedars-Sinai, Marinus Pharmaceuticals, Brii Biosciences Limited, and others.
Bipolar Depression Market
Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others.
Treatment-resistant Depression Market
Treatment-resistant Depression Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key TRD companies including Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP